Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Tango Therapeutics, Inc. - Common Stock (NQ:TNGX)

30.93 +10.71 (+52.97%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Tango Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
Tango Therapeutics Announces Proposed $500 Million Public Offering
From Tango Therapeutics, Inc.
Via GlobeNewswire
These stocks are moving in today's session ↗
Via Chartmill
Top stock movements in today's session. ↗
Via Chartmill
These stocks are gapping in today's session ↗
Via Chartmill
News headline image
Earnings Scheduled For November 4, 2025 ↗
 
Via Benzinga
News headline image
A Peek at Tango Therapeutics's Future Earnings ↗
 
Via Benzinga
Monday's pre-market session: top gainers and losers ↗
Via Chartmill
News headline image
Tango Therapeutics Announces Combination of Vopimetostat and Daraxonrasib Demonstrated 92% Objective Response Rate in Pancreatic Cancer
From Tango Therapeutics, Inc.
Via GlobeNewswire
News headline image
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Tango Therapeutics, Inc.
Via GlobeNewswire
News headline image
Tango Therapeutics Stock Is Up 840%, and This Fund Just Disclosed Buying $164 Million More ↗
This biotechnology firm advances targeted cancer therapies, leveraging genetic insights and strategic partnerships in oncology. 
Via The Motley Fool
News headline image
Acuta Capital Sells 56% of Ocular Therapeutix Shares in Q1 ↗
Ocular Therapeutix delivers FDA-approved eye therapies and devices, supported by a pipeline targeting multiple ocular diseases. 
Via The Motley Fool
Topics Regulatory Compliance Stocks
News headline image
Boxer Capital’s $18 Million Corvus Pharma Bet Signals Confidence in This Biotech’s Next Phase ↗
Corvus Pharmaceuticals develops immuno-oncology therapies, advancing clinical candidates for cancer and immune-related conditions. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why One Healthcare Fund Increased Its Kodiak Sciences Stake Amid an Eye-Popping Rally ↗
This clinical-stage biotech develops innovative retinal disease therapies, with its lead candidate advancing through late-stage trials. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Vir Biotechnology Stock Has Doubled This Past Year. One Fund Just Bought 1.2 Million Shares ↗
Vir Biotechnology develops antibody and RNA-based therapies for infectious diseases, leveraging partnerships and a robust clinical pipeline. 
Via The Motley Fool
News headline image
Acuta Capital Bet on Erasca (ERAS) and Targeted Cancer Treatments With a 354,575 Share Buy ↗
This San Diego biotech develops targeted therapies for RAS/MAPK-driven cancers, advancing several clinical candidates in oncology. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Tango Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights
From Tango Therapeutics, Inc.
Via GlobeNewswire
News headline image
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Tango Therapeutics Sub, Inc
Via GlobeNewswire
News headline image
Tango Therapeutics Announces Leadership Appointments to Accelerate Late-Stage Development of Vopimetostat
From Tango Therapeutics Sub, Inc
Via GlobeNewswire
News headline image
Tango Therapeutics President Sells 27,000 Shares for $572,000 as Share Price Skyrockets ↗
This precision oncology developer reported a notable insider sale during a period of robust share price gains. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Tango Therapeutics Insider Sells $304,000 in Stock Amid a 36% Single-Day Surge ↗
This clinical-stage biotech focused on targeted cancer therapies reported a notable insider sale. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Is Relay Therapeutics a Buy in 2026? One Institutional Investor Just Made a $6 Million Bet. ↗
Relay Therapeutics develops precision oncology medicines using proprietary computational modeling and strategic industry partnerships. 
Via The Motley Fool
News headline image
Nextech Trims Kymera at a Recent High — think Foolishly before acting. ↗
Kymera Therapeutics develops targeted protein degradation therapies for immunology and oncology, advancing a diversified clinical pipeline. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
The Patent Cliff is Coming, Driving Smart Money Towards Precision Oncology
Issued on behalf of Oncolytics Biotech Inc. 
From Equity Insider
Via GlobeNewswire
News headline image
Investment Firm Doubles Down on Biotech Stock, Adds 386,000 Shares, According to Recent SEC Filing ↗
This clinical-stage biotech targets retinal diseases with late-stage drug candidates and a focused pipeline in ophthalmology. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Investment Manager Loads Up on CELC Stock, Adds 135,000 Shares, According to Latest SEC Filing ↗
This clinical-stage biotech develops precision oncology therapies and diagnostics targeting unmet needs in breast and ovarian cancer. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Investment Firm Builds Position in TERN Stock, According to Recent SEC Filing ↗
This clinical-stage biotech develops small-molecule therapies for liver and metabolic diseases, targeting unmet needs in NASH and obesity. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Investment Firm Bets Big on TNGX Stock With $9.5 Million Purchase, According to Recent SEC Filing ↗
This clinical-stage biotech develops targeted cancer therapies, leveraging strategic partnerships and a differentiated oncology pipeline. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
The $20 Billion Question: Revolution Medicines Surges as Big Pharma Circles the Pan-RAS Leader
The first week of 2026 has set the biotech sector ablaze, with Revolution Medicines (NASDAQ: RVMD) finding itself at the epicenter of a high-stakes acquisition tug-of-war. Shares of the Redwood... 
Via MarketMinute
Topics Intellectual Property
News headline image
TANGO THERAPEUTICS INC (NASDAQ:TNGX) Posts Strong Q3 Earnings Beat Amid Mixed Market Reaction ↗
Tango Therapeutics (TNGX) reported a strong Q3, beating revenue and EPS estimates. Despite the earnings beat, the stock saw mixed market reaction. 
Via Chartmill
Topics Earnings
News headline image
Is Tango Therapeutics Stock a Buy, Sell, or Hold After Major Shareholder Third Rock Ventures Sold Nearly Half a Million Shares? ↗
Is Tango Therapeutics Stock a Buy, Sell, or Hold After Major Shareholder Third Rock Ventures Sold Nearly Half a Million Shares? 
Via The Motley Fool
Topics Regulatory Compliance
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.